Bullet Biotechnology
Menlo Park
About Bullet Biotechnology
Bullet Biotechnology is an innovative biotech company developing powerful products that will train a patient's own immune system to fight disease. Using our proprietary protein nanoparticles, we create powerful immunotherapies to target cancer. Their initial product dramatically improves response rates to checkpoint inhibitors such as anti-PD1 and anti-CTLA4 and will be developed for solid tumors. Bullet Biotech’s experienced management team is taking a practical approach to building and realizing value for patients and investors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $2.2M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Jun 2016)
- Website: bulletbio.com
- Phone: (650)278-8958
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/bullet-biotechnology-169365 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.